The power of patient advocacy in cancer care
Larry, a retired US Navy veteran, and Jeff, UICC President, have more in common than a cancer diagnosis: they share a passion for patient empowerment.
Search
Health equity for underserved communities
Introducing initiatives that improve access to healthcare for underserved communities
Approval for Aservo EquiHaler equine asthma therapy
Boehringer Ingelheim receives approval for Aservo® EquiHaler®, industry first equine asthma therapy
Henke-Sass Wolf develop needle free device
Boehringer Ingelheim partners with Henke-Sass, Wolf to develop innovative needle free injection device for pigs
antibiotic resistance one health veterinary medicine
Antimicrobial resistance is a major global threat to the health of humans and animals alike. Learn about challenges and solutions here.
Our partners Bioveta
Our partner Bioveta shares insights about the longstanding collaboration with Boehringer Ingelheim and the evolution of the partnership
Boehringer Ingelheim advances SIRP immune-oncology program
Boehringer and OSE Immunotherapeutics advance clinical development of first-in-class SIRP cancer immunology treatment BI 770371
Access to Healthcare Strategy Sustainable Access Models
Boehringer Ingelheim aspires to be a leader in ensuring improved access by delivering more health to humans, animals and communities around the world. Read more about our holistic approach, based on partnerships and local empowerment.
Inauguration of new global center for veterinary vaccine R&D
Inauguration of a new global hi-tech centre for biological research and development in Lyon.
2018 Animal Welfare Medals
2018 Animal Welfare Medals: Boehringer Ingelheim recognizes outstanding research in cattle, equine, swine, as well as small animals and pet categories
Boehringer Ingelheim and GST prepared bring innovation to equine market
Boehringer Ingelheim and Global Stem Cell Technology are prepared to bring groundbreaking innovation to equine market
Veterinary oncology - cancer treatment
Our R&D team's efforts toward finding new cancer treatments for pets
Lyon
The Lyon region is a key global hub for the Animal Health business of the company, encompassing research, development, production and supply of veterinary products.
About cardio-renal-metabolic conditions
This page provides an overview of cardiovascular, renal, and metabolic conditions
Open Innovation at Boehringer Ingelheim
Learn more about how we’re working across the innovation community to advance research and accelerate the development of new medicines
Celebrating 20 years of Metacam for cattle
Celebrating 20 years of Metacam (Meloxicam) for cattle
cystic fibrosis phase II trial
The first patient has been enrolled in a phase II trial to evaluate an innovative treatment for cystic fibrosis, inhaled via the Respimat® inhaler
Launch of BVDzero scholarship for veterinary students
Launch of BVDzero scholarship for veterinary students globally
New positive data in Phase III type 2 diabetes trial
DINAMO Phase III trial demonstrated empagliflozin significantly reduced blood sugar levels in children and adolescents with type 2 diabetes
Option to Acquire Trutino Biosciences
Option to Acquire Trutino Biosciences
In-Reach Africa initiatives successfully completed
We are proud to report the successful completion of Kuza Afya and Tiba Yako, two of our In-Reach Africa initiatives.
Boehringer Ingelheim Access to Healthcare Strategy last mile
We aspire to be a leader in ensuring improved access by delivering more health to humans, animals and communities around the world.
Arti-cell Forte stem cell-based veterinary product
Boehringer Ingelheim launches the first-ever registered stem cell-based veterinary medicine
Thelaziosis dog eyeworms
Have you heard of Thelaziosis? In Europe, some fruit flies host an emerging parasite known as “eyeworm”, an infestation which causes more or less severe conjunctivitis, sometimes leading to corneal ulcers and even blindness in dogs.
founding-member-of-QUTAC
Together, the members of this newly founded consortium want to explore industrial applications for quantum computing